WHO WE ARE
ABOUT VIROTECH
Guangzhou Virotech Pharmaceutical Co., Ltd. (Virotech), founded in January 2015 by Professor Yan Guangmei’s original research team from Sun Yat-sen University, is headquartered at the Guangzhou International Business Incubator. Virotech specializes in developing innovative oncolytic virus therapies with a strong focus on First-in-Class and Best-in-Class treatments, striving to pioneer oncolytic viral technologies that target cancers at their root.
Since its establishment, Virotech has received numerous honors, including recognition as one of the Top 50 Most Innovative Chinese Biopharmaceutical Enterprises, a Guangdong Province Specialized and Innovative SME, and a Guangzhou Future Unicorn Enterprise. Today, Virotech stands among the leading biopharmaceutical companies within its niche industry.
At the core of Virotech’s innovation is the groundbreaking oncolytic virus M1 (OVM), distinguished by three major advantages:
● Precision targeting
● Intravenous delivery
● Freeze-dried formulation
The OVM technology portfolio encompasses 88 patent applications spanning 22 countries and regions, with 60 patents already granted. Recognizing these pioneering advancements, Virotech’s core patents received the prestigious 23rd China Patent Award (Silver), and several others have been selected among the Top 100 Patents of Guangzhou Development Zone.
88 patent applications have been filed for this technology
Covering 22 countries and regions
60 authorizations have been granted
CORE ADVANTAGES
Companion Diagnostics
Overcoming trial and error, achieving precise healing
Intravenous injection
Treatment of deep tumors and metastatic tumors
Powder for injection
Convenient for storage, transportation, and use
Companion Diagnostics
Eliminate trial-and-error by enabling biomarker-driven precision therapy
Intravenous injection
Enable effective treatment of deep-seated and metastatic tumors
Freeze-dried Powder for Injection
Ensure convenient storage, transport, and administration
CHAIRMAN'S INTRODUCTION
GUANGMEI YAN
CHAIRMAN AND CHIEF SCIENTIST, VIROTECH
● Former Vice President of Sun Yat-sen University, academic lead of the original oncolytic virus M1 research team, and editor-in-chief of the Ministry of Education’s nationally designated textbook Pharmacology. Recipient of the State Council Special Allowance for outstanding scientific and technological contributions.
● Conducted research and development at the U.S. National Institute of Mental Health (NIMH/NIH), Eli Lilly, and Indiana University.
● Authored over 100 peer-reviewed articles in international SCI-indexed journals.
● Under his leadership, the oncolytic virus M1 research team was recognized by international media as the “Top One” global academic institution in the field of oncolytic virotherapy.
CORE TEAM MEMBER
● The core technical team consists of top talent from leading universities such as Peking University, Sun Yat-sen University, China Pharmaceutical University, and South China University of Technology, as well as professionals from industry-leading pharmaceutical companies including Dongyang Sunshine and Kangfang Bio.
● The team includes high-level experts recognized as National Outstanding Youth, Guangdong Outstanding Youth, Pearl River Scholars, and elite talents honored by the local development zone.
● Core members bring over ten years of experience in CMC, non-clinical research, clinical development, and new drug registration.
● The team has deep expertise in innovative drug development that aligns with regulatory standards in China, the United States, and other major markets.
● Successfully advanced several innovative cell and gene therapy (CGT) products through multi-country regulatory submissions.
COOPERATION UNIT
Focus on us
Contact Information
Monday to Friday 9:00~17:00
Rooms 801-808 and 901-908, Building H, No. 3 Jiu Quan Road, Huangpu District, Guangzhou City
Copyright©2024 Virotech Pharmaceutical Technology Co., Ltd.
